Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads In Cellular Therapy Cellular Therapy for November/December 2019 PT-Cy bests conventional GVHD prophylaxis, Off-the-shelf cellular therapy shows promise in the lab, Bispecific CAR T-cells yield high response rate in relapsed/refractory myeloma, High complete response rate seen with novel CAR-T for myeloma, Will TP53-mutated AML respond to immunotherapy?, More must reads Cellular Therapy for September/October 2019 CAR T-Cell Therapy Found Safe, Effective For HIV-Associated Lymphoma, CT103A elicits responses after prior CAR T-cell relapse, More must readsCellular Therapy for May/June 2019 Low intensity bridging may be best path to CAR T in adult ALL, More must readsCellular Therapy for March/April 2019 Gene therapy restored immunity in newly diagnosed SCID-X1, Infant Survival Rate Flat in Infants After HCT, Ixazomib targets treatment failure in chronic GVHD, MRD status at transplant predicts outcomes in ALL patients, Secondary AML in first remission predicts outcomes, More must readsCellular Therapy for January/February 2019 CLL, GVHD may raise risk for skin cancer after allo-HCT, Ultrasound method predicts liver complications in pediatric transplant, Treosulfan may become standard in allo-HCT for AML/MDS, Anti-GM-CSF antibody reduced CAR T-cell toxicity, MRD negativity linked to survival in MM after auto-HCT, More must readsPages1 2 3 4 next › last »
